Phase 3 Study Comparing Intravenous ABBV-706 to Standard Treatments for Adults with Relapsed or Refractory Small Cell Lung Cancer

What this Trial Is About

Small cell lung cancer SCLC is a fast-growing and aggressive cancer that often spreads early to areas such as lymph nodes, liver, bones, adrenal glands, and brain. This trial is assessing the safety, tolerability, and changes in disease activity of an investigational drug called ABBV-706 compared to standard treatments including topotecan, lurbinectedin, or amrubicin. The study is a Phase 3 randomized trial involving adults with relapsed or refractory SCLC who have received prior therapy. Participants in this study are randomly assigned to receive either intravenous ABBV-706 or one of the standard care treatments topotecan, given intravenously or orally lurbinectedin intravenously or amrubicin intravenously. The study duration is approximately 53 months, with treatments and assessments occurring during this period. The trial is conducted across multiple sites worldwide. During the study, participants will have regular visits to hospitals or clinics for various medical assessments including blood tests, scans, and questionnaires to monitor their health and disease status. Researchers will measure outcomes such as tumor response, overall survival, progression-free survival, duration of response, and quality of life changes. Safety and adverse events will also be monitored throughout the trial period.

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer